LEGN (Legend Biotech) Long-Term Debt : $296.6 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Long-Term Debt?

Legend Biotech's Long-Term Debt for the quarter that ended in Sep. 2024 was $296.6 Mil.

Legend Biotech's quarterly Long-Term Debt increased from Mar. 2024 ($286.4 Mil) to Jun. 2024 ($291.6 Mil) and increased from Jun. 2024 ($291.6 Mil) to Sep. 2024 ($296.6 Mil).

Legend Biotech's annual Long-Term Debt increased from Dec. 2021 ($120.5 Mil) to Dec. 2022 ($260.9 Mil) and increased from Dec. 2022 ($260.9 Mil) to Dec. 2023 ($281.3 Mil).

Legend Biotech Long-Term Debt Historical Data

The historical data trend for Legend Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Long-Term Debt Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

120.46

260.93

281.33

Legend Biotech Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Long-Term Debt	Get a 7-Day Free Trial															275.91	281.33	286.40	291.56	296.62

Legend Biotech (NAS:LEGN) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Legend Biotech Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.